Syg Inc

WATER/SEWER IMPROVEMENTS

WATER SYSTEM IMPROVEMENT

TELEMEDICINE GRANT

SBIR PHASE II: SPATIAL LIGHT MODULATOR FOR LONG WAVELENGTH IMAGING

TAS::89 0331::TAS RECOVERY ACT BLOCK GRANT FOR ARRA FUNDING. NEW AWARD FOR JOHNSTON COUNTY BOARD OF COMMISSIONERS. JOHNSTON, NC

WASTEWATER IMPROVEMENTS

ASSISTANCE TO FIREFIGHTERS GRANT

PURPOSE: TRACEABLE REFERENCE STANDARDS IS BECOMING AN INDISPENSABLE TOOL FOR PHARMACEUTICAL COMPANIES TO IDENTIFY THERAPEUTIC TARGETS AND PHARMACODYNAMIC BIOMARKERS. THIS ADVANCEMENT WILL ACCELERATE THE DEVELOPMENT OF PRECISION MEDICINE, MAKING SPATIAL METABOLOMICS A HIGHLY IMPACTFUL DRUG DISCOVERY AND DEVELOPMENT PLATFORM. SYGNAMAP AIMS TO TACKLE THIS CHALLENGE BY FURTHER DEVELOPING A COMPUTATIONAL QUANTITATIVE NORMALIZATION APPROACH ENHANCING THE RELIABILITY AND APPLICABILITY OF SPATIAL METABOLOMICS IN DRUG DEVELOPMENT.POTENTIAL COMMERCIALSACTIVITIES TO BE PERFORMED: DEVELOP A COMPUTATIONAL QUANTITATIVE NORMALIZATION APPROACH FROM CALIBRATION STANDARDS THAT WILL IMPROVE THE APPLICATION OF MALDI-MSI IN DRUG DEVELOPMENT.EXPECTED OUTCOMES: THE ACHIEVEMENTS REALIZED IN ITS SBIR PHASE I PROJECT WILL CARRY OVER TO THIS PHASE II PROJECT WHERE SYNAMAP WILL EXPAND INTO DEVELOPING A COMPUTATIONAL QUANTITATIVE NORMALIZATION APPROACH FROM CALIBRATION STANDARDS.INTENDED BENEFICIARIES: RECIPIENT'S INTENDED BENEFICIARIES INCLUDE BIOTECH AND PHARMACEUTICAL COMPANIES INTERESTED IN THERAPEUTIC TARGET AND BIOMARKER DISCOVERY.SUBRECIPIENT ACTIVITIES: THE RECIPIENT DOES NOT INTEND TO MAKE SUBAWARDS FOR THIS PHASE II PROJECT.

QUANTITATIVE NORMALIZATION OF SPATIAL METABOLOMICS FOR MOLECULAR SIGNATURES OF TISSUE HETEROGENEITY - PROJECT SUMMARY THE MOLECULAR AND BIOCHEMICAL BASIS OF TISSUE HETEROGENEITY IN NORMAL AND DISEASE STATES CAN BE ADDRESSED WITH SPATIAL OMIC ANALYSIS. ADVANCES IN SPATIAL METABOLOMIC ANALYSIS OF TISSUE BIOPSIES USING MALDI-MSI COULD ENABLE THE IDENTIFICATION OF NUMEROUS BIOCHEMICAL PATHWAYS AS SIGNATURES OF SPECIFIC HISTOPATHOLOGY FEATURES. HOWEVER, TO EXTRACT THE MOST ROBUST DISEASE- RELEVANT BIOMARKERS AND PATHWAYS FROM SPATIAL OMICS PLATFORMS WILL REQUIRE QUANTITATION OF SPATIAL MOLECULES FOR AUTOMATION AND STATISTICAL ANALYSIS. A KEY OBSTACLE TO ADOPTION OF SPATIAL METABOLOMICS IS THE LACK OF RIGOROUS NORMALIZATION OF BIOMOLECULES ACROSS TISSUE SECTIONS. SYGNAMAP PROPOSES TO BUILD MSI-DEEPPATH AS A COMPUTATIONAL PLATFORM TO QUANTIFY SPATIALLY DISTINCT METABOLITE ABUNDANCIES WITH HISTOPATHOLOGIC FEATURES. DATA FROM MALDI-MSI AND BULK METABOLOMICS FROM SERIAL SECTIONS OF HUMAN KIDNEY AND LIVER TISSUE WILL BE USED AS THE DATA SOURCE FOR OUR PLATFORM DEVELOPMENT. SYGNAMAP IS DEVELOPING MSI-DEEPPATH, A DRUG DISCOVERY AND DEVELOPMENT COMPUTATIONAL PLATFORM THAT INCORPORATES GROUND-BREAKING IMPROVEMENTS IN MALDI- MSI WITH COMPUTATIONAL PATHOLOGY. QUANTITATION OF SPATIAL METABOLOMICS FOR AUTOMATION AND STATISTICAL ANALYSIS AS PRESENTED IN THIS SBIR PROPOSAL WILL ENABLE THE EXTRACTION OF THE MOST ROBUST DISEASE-RELEVANT PATHWAYS FROM METABOLITES. THE RIGOROUS DECONVOLUTION OF STRUCTURE-RELEVANT PATHWAYS WILL ENABLE A HIGHLY IMPACTFUL THERAPEUTIC TARGET DISCOVERY AND DRUG DEVELOPMENT PLATFORM FOR USE BY BIOTECH AND PHARMACEUTICAL COMPANIES FOR DEVELOPMENT OF THERAPEUTICS ALONGSIDE BIOMARKERS.

ASSISTANCE TO FIREFIGHTERS GRANT

ON-CHIP FILTRATION AND FRACTIONATION COMPONENTS FOR HIGH-SENSITIVE POC DEVICE TO MEASURE CHIRAL METABOLITES IN URINE - PROJECT SUMMARY: IN DIAGNOSIS OF CHRONIC DISEASES SUCH AS CANCER, DIABETES, KIDNEY DISEASE, AND NEUROLOGIC DISEASE, URINE METABOLITES ARE INCREASINGLY BEING USED TO STRATIFY PATIENTS FOR CLINICAL TRIALS. MANY OF THE METABOLITES ARE CHIRAL WITH D- AND L- ENANTIOMERS. THESE ENANTIOMERS ARE OFTEN PRODUCED VIA DIFFERENT MOLECULAR PATHWAYS AND CAN HAVE SIGNIFICANTLY DIFFERENT BIOLOGICAL FUNCTIONS. QUANTITATION OF CHIRAL METABOLITES IN BIOFLUIDS (URINE AND BLOOD) CAN BE USED AS AN IN VITRO DIAGNOSTIC AND COMPANION DIAGNOSTIC TO GUIDE PATIENT STRATIFICATION AND CHOICE OF A SPECIFIC THERAPEUTIC. CONVENTIONAL POCS OR ANALYTICAL METHODS ARE LIMITED BECAUSE THEY ONLY MEASURE SINGLE METABOLITES OR SINGLE CHIRAL METABOLITE AT A GIVEN TIME. MEASUREMENT OF MULTIPLE CHIRAL METABOLITES IS CHALLENGING AND EXPENSIVE, OFTEN REQUIRES OPTIMIZATION OF MASS SPECTROMETRY TECHNIQUES AND TAKES HOURS TO DAYS TO COMPLETE. THE LIMITATIONS OF THE EXISTING METHODS RENDER MEASUREMENTS OF CHIRAL METABOLITES IMPRACTICAL FOR SPEEDY DECISIONS NEEDED FOR CLINICAL TRIALS OR PATIENT CARE. NEW DEVICES AND TECHNOLOGIES ARE URGENTLY NEEDED FOR A FAST, ACCURATE AND SIMULTANEOUS MEASUREMENT OF MULTIPLE CHIRAL METABOLITES. TO THIS END, WE PROPOSE TO DEVELOP A NEW POINT OF CARE DEVICE WHICH COULD RAPIDLY AND COST-EFFECTIVELY MEASURE MULTIPLE CHIRAL METABOLITES WITH HIGH SENSITIVITY. OUR INNOVATION IS THE DEVELOPMENT OF AN INTEGRATED OPTOFLUIDIC DEVICE WITH PLASMONIC METAMATERIALS THAT GREATLY ENHANCE DETECTION OF CHIRALITY AND IMPROVE SENSITIVITY OF MEASUREMENT AS MUCH AS 107-FOLD IN <10 UL OF BIOFLUIDS. IN PHASE I WE WILL FOCUS ON DEVELOPING CAPABILITIES TO FILTER AND FRACTIONATE THE BIOFLUID AND QUANTIFY THE CHIRAL MOLECULES FROM BIOFLUIDS. THIS NOVEL MULTIPLEX TECHNOLOGY WILL ENHANCE AND RAPIDLY PERFORM CHIRALITY IDENTIFICATION AND QUANTIFICATION IN BIOFLUIDS LEADING TO SIGNIFICANT COST SAVING AND PROMOTE PRECISION MEDICINE.

PRECISION MASS SPEC IMAGING BASED STRUCTURE-FUNCTION SIGNATURES OF DIABETIC GLOMERULOPATHY - PROJECT SUMMARY/ABSTRACT THERE ARE CURRENTLY >450,000 PATIENTS ON DIALYSIS AND ~120,000 PATIENTS WILL HAVE TO BEGIN DIALYSIS EACH YEAR IN THE UNITED STATES. ALONG WITH A MARKED REDUCTION IN QUALITY OF PATIENT LIFE, THE COST TO THE US MEDICARE SYSTEM IS IN EXCESS OF $114B PER YEAR. THEREFORE, THERE IS AN URGENT NEED FOR DEVELOPING NEW PLATFORMS THAT WILL ENHANCE THE DRUG DEVELOPMENT PROCESS FOR NEW THERAPIES TO REDUCE THE RATE OF PROGRESSION TO END-STAGE KIDNEY DISEASE. NON-INVASIVE BIOMARKERS MAY BE USEFUL BUT DO NOT DIRECTLY IDENTIFY THE PATHWAYS LINKED TO PATHOLOGY IN THE KIDNEY. AN APPROACH THAT INTEGRATES TISSUE STRUCTURE WITH FUNCTIONAL READOUTS IN A KIDNEY BIOPSY WOULD BE A MAJOR ADVANCE. WE ARE DEVELOPING A COMPUTATIONAL PLATFORM THAT LEVERAGES MASS SPEC IMAGING DATA COUPLED WITH COMPUTATIONAL PATHOLOGY FOR KIDNEY TISSUE AS A TECHNOLOGY THAT WILL ADDRESS THIS UNMET NEED. WITH OUR COMPUTATIONAL PLATFORM WE CAN IDENTIFY SIGNATURES LINKED TO NORMAL AND ABNORMAL PATHOLOGY ON THE SAME TISSUE SECTION. THIS IS A POWERFUL APPROACH TO UNDERSTAND KIDNEY PATHOLOGY AND WILL BE OF GREAT VALUE FOR DRUG DEVELOPMENT FOR KIDNEY DISEASE. PARAMETERS RELATED TO REPRODUCIBILITY ACROSS PRE-CLINICAL MODELS OF DIABETIC KIDNEY DISEASE INTERPRETATION WILL BE OPTIMIZED DURING PHASE I. UPON COMPLETION OF THE SBIR PHASE I PROJECT WE WILL HAVE RIGOROUS DATA TO DETERMINE CONSISTENCY OF DISEASED GLOMERULAR SIGNATURES IN DIABETIC NEPHROPATHY. THIS PROOF OF CONCEPT DATA WILL MAKE IT ATTRACTIVE TO PHARMA AND BIOTECH TO ADOPT THIS PLATFORM FOR APPLICATION FOR THEIR THERAPEUTIC PROGRAMS FOR DIABETIC KIDNEY DISEASE.

SBIR PHASE I: COMPUTATIONAL PLATFORM TO INFER PUTATIVE CAUSATIVE PATHWAYS OF PATHOLOGY USING SPATIAL OMICS DATA -THE BROADER IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT WILL BE TO IMPROVE CLINICAL OUTCOMES AND QUALITY OF LIFE FOR KIDNEY DISEASE. THIS TECHNOLOGY WILL HELP IDENTIFY BIOMARKERS AND ENABLE NEW PERSONALIZED TREATMENTS TO IMPROVE EFFICACY AND REDUCE HARMFUL SIDE EFFECTS. THE INNOVATION WILL LEVERAGE NEW ENHANCEMENTS IN VISUALIZING MOLECULES IN BIOLOGICAL SAMPLES AND WILL IMPROVE SCIENTIFIC UNDERSTANDING OF COMPLEX DISEASES. THE PROPOSED PROJECT WILL LEVERAGE THE POWER OF THE EMERGING FIELD OF SPATIAL OMICS TO BUILD A NOVEL COMPUTATIONAL PLATFORM. MULTI-OMICS TECHNOLOGY AT A SPATIAL LEVEL IS CHANGING OUR UNDERSTANDING OF COMPLEX CONDITIONS, SUCH AS CANCER AND METABOLIC DISEASES. THESE TECHNOLOGIES ARE IMPORTANT TO BETTER UNDERSTAND HETEROGENEITY OF NORMAL ORGAN STRUCTURE AND CHANGES DURING THE DEVELOPMENT OF COMPLEX CHRONIC METABOLIC DISEASES AND CANCERS. MASS SPECTROMETRY-BASED PLATFORMS HAVE LED MULTI-OMIC SPATIAL APPLICATIONS, BUT QUANTIFYING THE OUTPUT OF MASS SPECTROMETRY IMAGING REMAINS A CHALLENGE. THE RESEARCH OBJECTIVES ARE TO CORRELATE AND OPTIMIZE LOCALIZATION OF MOLECULES WITH PATHOLOGIC FEATURES AND IDENTIFY KEY BIOCHEMICAL PATHWAYS THAT DRIVE DISEASE DEVELOPMENT. THE METHODS WILL INCLUDE COMPUTATIONAL PATHOLOGY, MASS SPECTROMETRY IMAGING, AND ARTIFICIAL INTELLIGENCE/ MACHINE LEARNING APPROACHES. THE ANTICIPATED TECHNICAL RESULTS WILL BE DEVELOPMENT OF TECHNOLOGIES THAT CONVERT SEMI-QUANTITATIVE OUTPUT TO RIGOROUS, QUANTITATIVE RESULTS FOR IDENTIFICATION OF PATHWAYS DRIVING DISEASE DEVELOPMENT. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

SBIR PHASE I: SPATIAL LIGHT MODULATOR FOR LONG WAVELENGTH IMAGING

ASSISTANCE TO FIREFIGHTERS GRANT

PURPOSE: THE PURPOSE OF THIS GRANT IS TO DEVELOP AN INNOVATIVE COMPUTATIONAL PLATFORM TO ANALYZE DATA FROM SPATIAL METABOLOMICS FOR USE IN DRUG DEVELOPMENT.ACTIVITIES TO BE PERFORMED: ESTABLISH CALIBRATION STANDARDS; DEVELOP A COMPUTATIONAL PLATFORM, VALIDATION OF RESEARCH ACTIVITIES.EXPECTED OUTCOMES: THE PHASE I PROJECT WILL ASSESS THE TECHNICAL VIABILITY OF THE RECIPIENTS COMPUTATIONAL MODEL AND SUPPORT PHASE II RESEARCH AND DEVELOPMENT OF ITS TECHNOLOGY.INTENDED BENEFICIARIES: HEALTH, MEDICAL AND PHARMACEUTICAL INDUSTRIES.SUBRECIPIENT ACTIVITIES: THE RECIPIENT PLANS TO SUBAWARD FUNDS FOR PROJECT DIRECTION, AND TO CONDUCT METABOLIC MEASUREMENT ACTIVITIES.

ASSISTANCE TO FIREFIGHTERS GRANTS

EWP PROJ 5038, MOCCASIN CK SD, JOHNSTON CO, CLEAR DEBRIS (600012763)

INDIAN EDUCATION FORMULA GRANTS TO LEAS

FISCAL YEAR 2010 JAG

INDIAN EDUCATION FORMULA GRANTS TO LEAS

INDIAN EDUCATION FORMULA GRANTS TO LEAS

PATROL TASER PROJECT

INDIAN EDUCATION FORMULA GRANTS TO LEAS

PROJECT TASER REPLACEMENT AND TRAINING

THE EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT (JAG) PROGRAM ALLOWS UNITS OF LOCAL GOVERNMENT, INCLUDING TRIBES, TO SUPPORT A BROAD RANGE OF ACTIVITIES TO PREVENT AND CONTROL CRIME BASED ON THEIR OWN STATE AND LOCAL NEEDS AND CONDITIONS. GRANT FUNDS CAN BE USED FOR STATE AND LOCAL INITIATIVES, TECHNICAL ASSISTANCE, TRAINING, PERSONNEL, EQUIPMENT, SUPPLIES, CONTRACTUAL SUPPORT, AND INFORMATION SYSTEMS FOR CRIMINAL JUSTICE OR CIVIL PROCEEDINGS, INCLUDING FOR ANY ONE OR MORE OF THE FOLLOWING PROGRAM AREAS: 1) LAW ENFORCEMENT PROGRAMS; 2) PROSECUTION AND COURT PROGRAMS; 3) PREVENTION AND EDUCATION PROGRAMS; 4) CORRECTIONS AND COMMUNITY CORRECTIONS PROGRAMS; 5) DRUG TREATMENT AND ENFORCEMENT PROGRAMS; 6) PLANNING, EVALUATION, AND TECHNOLOGY IMPROVEMENT PROGRAMS; 7) CRIME VICTIM AND WITNESS PROGRAMS (OTHER THAN COMPENSATION); 8) MENTAL HEALTH PROGRAMS AND RELATED LAW ENFORCEMENT AND CORRECTIONS PROGRAMS, INCLUDING BEHAVIORAL PROGRAMS AND CRISIS INTERVENTION TEAMS; AND 9) IMPLEMENTATION OF STATE CRISIS INTERVENTION COURT PROCEEDINGS AND RELATED PROGRAMS OR INITIATIVES, INCLUDING BUT NOT LIMITED TO: MENTAL HEALTH COURTS; DRUG COURTS; VETERANS COURTS; AND EXTREME RISK PROTECTION ORDER PROGRAMS.

LAW ENFORCEMENT GEAR

J.C.S.O. PHOTOGRAPHY UPDATE AND UPGRADE PROJECT

REPLACEMENT OF OLD AND OUT DATED GAS MASKS (APR).

FY 19 LOCAL JAG

FY 17 JAG PROGRAM

PROJECT PATROL TASER

LAST PHASE OF REPLACEMENT OF PATROL SHOTGUNS TO ROUTINE PATROL RIFLES

PROJECT PATROL TASER

SCAAP

RADIO UPGRADE FOR THE JOHNSTON COUNTY SHERIFF'S OFFICE